Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

13
Tiffany's (TIF) Omnichannel, Product Portfolio to Lift Sales

2018-06-27 zacks
Industry experts believe that the luxury goods market is likely to remain healthy, courtesy of steady economic growth, higher consumer confidence and rising disposable income. Given this scenario, it will be wise to focus on some luxury goods’ stocks. Here we have highlighted one such stock Tiffany & Co. (TIF - Free Report) , which holds a significant position in the world jewelry market due to its distinctive brand appeal.
MOV GOOS FOSL LUXTY

2
3 Reasons Why You Should Snap Up Tiffany (TIF) Right Now

2018-06-15 zacks
Tiffany & Co. (TIF) is flexing muscle to counter competition in the jewelry industry. The company, which has a long-term expected earnings growth rate of 11.8%, is banking on several strategic initiatives to enhance customer base.
SCVL URBN FOSL LUXTY

0
Ray-Ban Just Dropped a $500 Pair of Aviators Plated in 24K Gold - Bloomberg

2018-06-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
LUXTY

0
Will Tiffany (TIF) Manage to See Higher Earnings in Q1?

2018-05-21 zacks
Tiffany & Co. (TIF - Free Report) is slated to report first-quarter fiscal 2018 results on May 23. In the trailing four quarters, this designer, manufacturer and retailer of jewelry and other items has outperformed the Zacks Consensus Estimate by an average of 4.5%. In the last reported quarter, the company delivered a positive earnings surprise of 2.5%. Investors are counting on another estimate beat by Tiffany in the to-be-reported quarter.
LUXTY

0
Luxottica (LUXTY) Q1 2018 Sales - Slideshow

2018-04-30 seekingalpha
The following slide deck was published by Luxottica Group, S.p.a. ADR in conjunction with this event.
LUXTY

1
With a Glance Backward, Brooks Brothers Looks to the Future - The New York Times

2018-04-23 nytimes
In early 2002, just a few months after he officially took over as the new owner and chief executive officer of Brooks Brothers, Claudio Del Vecchio confronted the reality that the classic American retailer had largely lost its way.
RL NYTAB LUXTY

52
Tiffany Strategizes to Lift Sales, Innovates to Woo Buyers

2018-04-18 zacks
As competition is intensifying in the retail space, Tiffany & Co. (TIF - Free Report) is leaving no stone unturned to drive revenues. The company, which has a long-term expected earnings growth rate of 11.2%, is banking on several strategic initiatives to enhance customer base. The company's strategic endeavors have helped the stock to gain 8.5% compared with the industry’s decline of 1.2% in the past six months.
JWN ABX KSS M ABX LUXTY

7
New Look Vision Group - A Closer Look At A Rising Presence

2018-03-14 seekingalpha
New Look Vision's growth strategy will allow them to take advantage of their economies of scale, as well as secure its position within the increasingly consolidated industry of optical retail.
EYE SAFLF BOSSY FLMNY KATE SAFLY HUGPF FLMNF BCI LUXTY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

6h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...